Equities

After examining all of our analysts’ buy-rated stocks with a market capitalisation above $1.0 billion, we have identified ten of them which we particularly like over the next 12 months or so for private clients.

The recent $30m placement significantly strengthens the PolyNovo balance sheet. We maintain a Buy rating, with a Price Target of $2.30.

BPT reported quarterly production of 5.2MMboe (BPe 5.4MMboe), down 8% QoQ, driven by major producing assets performing below expectations, particularly at Western Flank and the Victorian Otways.

CGC’s CY22e trading update quantifies the impact of the citrus quality issues while highlighting reasonable trading conditions across the remainder of the portfolio.

The first quarter of fiscal 2023 has proved to be another exceptionally challenging period for global equity markets.

We initiate coverage of DRO with a BUY recommendation and a 12 month price target of $0.24.